WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 6, 160-181. Review Article ISSN 2277–7105

APPLICATION OF ANALYTICAL QUALITY BY DESIGN IN CHROMATOGRAPHIC METHOD DEVELOPMENT: A PHARMACEUTICAL PERSPECTIVE

Siddhi Kadam*[1], Amruta Ghule[2], Prof. R. S. Bandal[3]

[1,2]M. Pharmacy Student, Department of Quality Assurance SVPM College of Pharmacy Malegaon Bk.

[3]Professor, QA Department, SVPM College of Pharmacy Malegaon Bk.

Article Received on 15 Feb. 2026,
Article Revised on 05 March 2026,
Article Published on 16 March 2026

https://doi.org/10.5281/zenodo.19043257

***Corresponding Author**
Siddhi Kadam
M. Pharmacy Student, Department of Quality Assurance SVPM College of Pharmacy Malegaon Bk.

How to cite this Article: Siddhi Kadam*[1], Amruta Ghule[2], Prof. R. S. Bandal[3] (2026). Application of Analytical Quality by Design in Chromatographic Method Development: A Pharmaceutical Perspective. World Journal of Pharmaceutical Research, 15(6), 160–181.

ABSTRACT

Analytical method development plays a critical role in ensuring the quality, safety, and efficacy of pharmaceutical products. Conventional chromatographic method development often relies on trial- and-error experimentation, which may lead to variability and limited robustness. Analytical Quality by Design (AQbD) has emerged as a systematic, science- and risk-based framework that enhances method understanding and reliability throughout the analytical lifecycle. The AQbD approach begins with defining the Analytical Target Profile (ATP), followed by identification of Critical Quality Attributes (CQAs) and Critical Method Parameters (CMPs) using risk assessment tools. Statistical techniques such as Design of Experiments (DoE) enable optimization of chromatographic conditions and establishment of the Method Operable Design Region (MODR), ensuring consistent performance within defined boundaries. Integration of lifecycle management, control strategy, and continuous monitoring further strengthens method robustness and regulatory flexibility. This review provides a comprehensive pharmaceutical perspective on the application of AQbD in chromatographic method development, highlighting key tools, regulatory expectations, advantages over traditional approaches, and current implementation challenges. Adoption of AQbD facilitates development of reliable, cost-effective, and regulatory-compliant chromatographic methods, ultimately supporting consistent pharmaceutical product quality.

KEYWORDS: Analytical Quality by Design (AQbD), Chromatographic method development, Design of Experiments (DoE), Critical Quality Attributes (CQAs), Method Operable Design Region (MODR), Pharmaceutical analysis.

1. INTRODUCTION

Analytical testing plays a central role in pharmaceutical development by ensuring drug quality, safety, and efficacy. Chromatographic techniques such as high-performance liquid chromatography are widely used for assay determination, impurity profiling, stability testing, and bio analysis.

Traditionally, chromatographic methods are developed using trial-and-error experimentation, where parameters are adjusted sequentially until acceptable performance is achieved. Although this approach may produce functional methods, it often lacks robustness, scientific understanding, and flexibility.

Quality by Design (QbD) introduced a paradigm shift by emphasizing systematic development based on predefined objectives, scientific knowledge, and risk management. Extending these principles to analytical procedures led to the emergence of Analytical Quality by Design (AQbD).

This approach focuses on understanding the relationship between analytical variables and method performance, enabling development of robust and reliable chromatographic methods.

The objective of this review is to discuss the application of AQbD in chromatographic method development from a pharmaceutical perspective, including framework, tools, applications, regulatory considerations, challenges, and future opportunities.

2. Overview of Quality by Design (QbD)

Quality by Design (QbD) is a systematic, science-based development approach that begins with clearly defined objectives and emphasizes comprehensive understanding of both product and process variables. Rather than relying primarily on end-product testing to confirm quality, QbD focuses on designing quality into the system from the outset through structured experimentation, risk evaluation, and knowledge management.

A central component of QbD is the Target Product Profile (TPP), which defines the intended clinical and quality characteristics of the product. Translating these objectives into

measurable parameters leads to identification of Critical Quality Attributes (CQAs)—physical, chemical, biological, or microbiological properties that must remain within specified limits to ensure product safety and efficacy.

Risk assessment is another key element of QbD, providing a structured approach to identify factors that may influence CQAs. By evaluating the severity, likelihood, and detectability of potential failures, developers can prioritize variables requiring detailed investigation. Following risk identification, experimental strategies are used to establish the design space, a multidimensional region of input variables within which product quality is consistently maintained. A well-defined control strategy ensures that knowledge gained during development is translated into routine practice. QbD also incorporates continuous improvement, recognizing that knowledge evolves over time.

Regulatory guidance increasingly promotes QbD to shift pharmaceutical development away from traditional "quality by testing" approaches. Agencies such as the U.S. Food and Drug Administration support frameworks that demonstrate scientific understanding and lifecycle control rather than reliance on final product verification alone. By integrating predefined objectives, risk management, statistical evaluation, and lifecycle thinking, QbD establishes a proactive model in which quality is built into the process—enhancing consistency, efficiency, and regulatory confidence across pharmaceutical systems.

3. Concept of Analytical Quality by Design (AQbD)

Analytical Quality by Design (AQbD) represents the application of Quality by Design principles to analytical method development. The AQbD philosophy emphasizes defining analytical objectives in advance, systematically understanding method variables, and ensuring that analytical performance remains consistent throughout its lifecycle. AQbD promotes continuous scientific understanding of how method parameters influence analytical outcomes.

The AQbD lifecycle typically follows a structured sequence beginning with method design, where analytical intent and performance requirements are defined and potential variables are identified. The next phase, method qualification, involves systematic experimentation—often supported by statistical tools—to understand the effect of critical parameters and to define suitable operating ranges. Method validation then confirms that the analytical procedure consistently meets predefined performance criteria under controlled conditions.

Compared with conventional analytical development strategies, AQbD offers several practical advantages. A structured understanding of parameter interactions enhances method robustness. By systematically identifying sources of variability, AQbD improves predictability. The knowledge generated during development also supports efficient troubleshooting, as potential causes of performance changes are already documented within the method understanding framework. AQbD enables regulatory flexibility within defined operating range. AQbD plays a particularly significant role in pharmaceutical analysis, especially in chromatographic techniques where multiple interacting variables influence separation quality, detection sensitivity, and quantitation accuracy.

Chromatographic systems are sensitive to changes in solvent composition, column characteristics, temperature, and instrument settings, making predictive understanding essential for reliable performance. By integrating predefined performance criteria, systematic optimization, and lifecycle monitoring, AQbD provides a comprehensive framework for managing this complexity.

4. AQbD Framework in Chromatographic Method Development

Analytical Quality by Design (AQbD) provides a structured pathway for developing chromatographic analytical methods. Instead of relying on trial-and-error experimentation, the AQbD framework systematically defines method objectives, identifies influential variables, evaluates risks, and establishes operating ranges. In chromatographic techniques such as RP-HPLC, where parameters simultaneously influence separation efficiency, the AQbD framework enhances method understanding and reliability.

The AQbD framework integrates multiple interrelated elements that collectively ensure that analytical methods remain robust for routine quality control.

4.1 Analytical Target Profile (ATP)

The Analytical Target Profile (ATP) represents the foundation of AQbD-based method development. It clearly defines the purpose of the analytical procedure and specifies measurable performance criteria required for its successful application. The ATP outlines attributes such as accuracy, precision, selectivity, detection capability, and allowable variability.

In chromatographic analysis, the ATP may specify requirements including minimum resolution between analyte and impurities, acceptable retention time variability, quantification limits, and assay accuracy ranges. By establishing these expectations at the outset, ATP guides experimental planning and ensures that method development activities remain aligned with regulatory and product quality requirements.

ATP also facilitates lifecycle management by serving as a reference point during method validation, transfer, and continuous monitoring.

Fig. 1. AQbD workflow diagram.

4.2 Critical Quality Attributes (CQAs)

Critical Quality Attributes (CQAs) are measurable outputs that indicate whether the analytical method is performing according to the ATP. These attributes directly reflect chromatographic separation quality and analytical reliability.

Common chromatographic CQAs include resolution between peaks, peak symmetry, tailing factor, retention time consistency, theoretical plate count, sensitivity, and signal-to-noise ratio.

The identification of CQAs enables developers to focus on performance indicators that are most relevant to method success.

Understanding CQAs helps establish acceptance criteria and provides a scientific basis for evaluating method robustness, ensuring that analytical variability does not compromise data integrity.

4.3 Critical Method Parameters (CMPs)

Critical Method Parameters (CMPs) refer to experimental variables that significantly

influence CQAs. In chromatographic method development, multiple parameters interact to affect separation behavior, making CMP identification essential.

Typical CMPs include mobile phase composition, buffer pH, column chemistry and particle size, flow rate, column temperature, injection volume, and detection wavelength. Variations in these parameters can alter retention behavior, peak shape, and sensitivity.

Systematic evaluation of CMPs allows analysts to understand parameter-performance relationships, enabling controlled optimization rather than empirical adjustments.

4.4 Risk Assessment

Risk assessment plays a central role in AQbD by identifying variables that have the greatest potential to impact method performance. Structured tools such as Ishikawa (fishbone) diagrams, Failure Mode and Effects Analysis (FMEA), and risk ranking matrices help prioritize parameters for further study.

Through risk assessment, developers can distinguish high-risk CMPs from less influential variables, ensuring efficient resource utilization. This step also supports regulatory expectations by providing documented justification for experimental focus and decision-making.

Risk-based thinking reduces method failure probability and enhances robustness by proactively addressing sources of variability.



Fig.2: Ishikawa Fishbone diagram.

4.5 Design of Experiments (DoE)

Design of Experiments (DoE) is a statistical methodology used to systematically evaluate the

effects of multiple CMPs and their interactions on CQAs. Unlike one-factor-at-a-time experimentation, DoE provides comprehensive insight into the multidimensional behavior of chromatographic systems.

Screening designs such as factorial or Plackett–Burman experiments help identify significant parameters, while optimization designs such as response surface methodology establish optimal operating conditions. DoE enables mathematical modeling of method performance, facilitating prediction of system behavior under varying conditions.

The application of DoE improves method efficiency, enhances understanding of parameter interactions, and reduces development timelines.



Fig.3. Plackett–Burman design (response surface methodology).

4.6 Method Operable Design Region (MODR)

The Method Operable Design Region (MODR) represents the multidimensional space within which CMP variations consistently meet predefined CQA criteria. Rather than defining a single optimal condition, MODR establishes acceptable operating ranges that ensure method robustness.

Operating within MODR allows flexibility during routine analysis, instrument variability, and method transfer across laboratories. This concept aligns with regulatory expectations by demonstrating process understanding and providing scientific justification for parameter ranges.

MODR reduces the need for frequent revalidation and supports lifecycle adaptability.



Fig.4: MODR design space plot.

4.7 Control Strategy

A control strategy ensures that the analytical method remains within the defined MODR during routine use. It includes system suitability criteria, parameter limits, monitoring procedures, and corrective actions.

System suitability tests commonly evaluate resolution, peak symmetry, retention time reproducibility, and sensitivity before sample analysis. Control strategies may also include periodic calibration, column performance monitoring, and documentation of environmental conditions.

A well-defined control strategy ensures consistent analytical performance and supports compliance with quality management systems.

4.8 Method Validation

Method validation confirms that the developed analytical procedure meets ATP requirements and is suitable for its intended purpose. Validation parameters typically include accuracy, precision, specificity, linearity, range, detection limit, quantification limit, and robustness.

Within the AQbD paradigm, validation is supported by prior method understanding generated through risk assessment and DoE. This knowledge-driven validation approach strengthens confidence in method reliability and reduces unexpected variability during routine application. Validation also facilitates regulatory submission and method transfer.

4.9 Lifecycle Management

Lifecycle management extends AQbD beyond initial development and validation. Continuous performance monitoring, trending of system suitability data, and periodic method review help ensure sustained analytical reliability.

Lifecycle management allows proactive identification of performance drift, supports method

improvement, and accommodates technological advancements. This ongoing oversight aligns with modern regulatory expectations that emphasize continuous verification rather than static validation. By integrating lifecycle thinking, chromatographic methods remain adaptable, efficient, and scientifically justified throughout their use

5. Application of AQbD in Chromatographic Techniques

The integration of Analytical Quality by Design (AQbD) into chromatographic analysis has transformed the way analytical methods are developed, optimized.

Chromatographic techniques inherently involve multiple interacting variables that influence separation quality, sensitivity, and reproducibility. AQbD provides a structured framework for systematic evaluation of these variables, ensuring consistent analytical performance across applications.

Across pharmaceutical research and quality control laboratories, AQbD has been successfully implemented in several chromatographic platforms. The following sections describe the role of AQbD across major chromatographic techniques.

5.1 Application in HPLC / RP-HPLC

High-performance liquid chromatography (HPLC), particularly reversed-phase HPLC (RP-HPLC), represents the most widely used analytical technique in pharmaceutical analysis.

The complexity of chromatographic separation — involving mobile phase composition, pH, column characteristics, temperature, and flow rate — makes RP-HPLC an ideal candidate for AQbD implementation.

Through AQbD, method objectives are first defined using the Analytical Target Profile, followed by identification of Critical Quality Attributes such as resolution, peak symmetry, and retention time. Critical Method Parameters including solvent ratio, buffer strength, column chemistry, and detection wavelength are then systematically evaluated using statistical experimental designs.

AQbD-based RP-HPLC methods are extensively applied in:

- Quantitative drug assay in finished dosage forms
- Impurity and degradation profiling
- Stability-indicating method development

– Combination drug analysis

The adoption of AQbD improves robustness. Furthermore, the establishment of a Method Operable Design Region allows flexibility in chromatographic conditions without compromising performance.

5.2 Application in UPLC

Ultra-performance liquid chromatography (UPLC) utilizes smaller particle size columns and higher operating pressures to achieve faster separations. While UPLC offers significant advantages in throughput, its performance is highly sensitive to minor variations in method parameters.

AQbD helps address this sensitivity by enabling systematic parameter evaluation and defining acceptable operating ranges. Statistical modeling identifies interactions among variables such as gradient profile, column temperature, flow rate, and injection volume.

The application of AQbD in UPLC is particularly valuable for

– High-throughput pharmaceutical analysis
– Rapid stability studies
– Bio analytical sample screening
– Process analytical technology support

By establishing robust design spaces, AQbD ensures that the benefits of UPLC — speed and efficiency — are achieved without compromising analytical reliability.

5.2 Application in HPTLC

High-performance thin-layer chromatography (HPTLC) is widely used for multi-component formulations where simultaneous analysis of numerous constituents is required. The complexity of plant matrices introduces variability in separation behavior, making systematic method development essential.

AQbD principles facilitate the identification of influential parameters such as mobile phase composition, chamber saturation conditions, application volume, and detection wavelength. Risk assessment and experimental design help optimize these variables to achieve consistent band resolution and reproducible densitometric quantification.

In HPTLC, AQbD supports

– Herbal formulation standardization
– Fingerprint profiling
– Multi-component drug analysis
– Quality control of nutraceuticals

The structured AQbD approach enhances reproducibility across batches and laboratories, which is particularly important for complex natural products.

5.3 Application in LC–MS

Liquid chromatography coupled with mass spectrometry (LC–MS) provides high sensitivity and selectivity for trace analysis. It is extensively used in impurity detection, metabolite identification, and bioanalysis. However, LC–MS performance depends on numerous factors including chromatographic separation, ionization efficiency, matrix effects, and instrument parameters.

AQbD enables a holistic evaluation of these factors by integrating chromatographic and mass spectrometric variables into experimental design. Parameters such as mobile phase additives, gradient profile, ion source conditions, and detector settings can be systematically optimized.

The implementation of AQbD in LC–MS is especially important for

5.3.1 Trace impurity profiling
5.3.2 Genotoxic impurity detection
5.3.3 Pharmacokinetic studies
5.3.4 Biomarker analysis
5.3.5 Stability and degradation pathway studies

Through enhanced method understanding, AQbD reduces variability caused by matrix effects and improves reproducibility in complex biological samples.

5.4 Overall Impact of AQbD Across Chromatographic Platforms

Evidence from published literature consistently demonstrates that AQbD enhances chromatographic method performance across different platforms.

Key benefits include

5.4.1 Reduction in development time through structured experimentation
5.4.2 Improved robustness due to defined design spaces

5.4.3 Better understanding of parameter interactions

5.4.4 Enhanced method reproducibility during transfer

5.4.5 Increased regulatory acceptance and lifecycle flexibility

5.4.6 Efficient troubleshooting and continuous improvement.

Table 1: Summary of reported AQbD-based chromatographic methods.

Drug/analyte	Technique	DoE applied	Key outcomes	Limitation	Reference
Drug substance impurities	RP-HPLC	Factorial design	Improved separation and robustness	Limited lifecycle discussion	Raman et al. [5]
Multiple APIs	RP-HPLC	Box-Behnken	Defined design space and optimized resolution	Limited real-time monitoring	Peraman et al.(21)
Pharmaceutical formulation	HPLC	Central composite design	Robust assay method with reduced variability	Software dependence	Sangshetti et al.[37]
Stability indicating method	RP-HPLC	Factorial screening	Identification of critical parameters	Narrow robustness range	Blessy et al. [19]
Drug impurities	UPLC	Response surface methodology	Rapid analysis with high efficiency	Equipment sensitivity	Fekete et al. [19]
Combination drug products	RP-HPLC	Box-Behnken	Simultaneous estimation with optimized resolution	Limited method transfer data	Kumar et al. [22]
Bio analytical compounds	LC-MS	Multivariate design	Enhanced sensitivity and selectivity	Matrix effects not fully addressed	Guillarme et al. (40)
General AQbD method	HPLC	DoE workflow	Better understanding of variability	Higher initial efforts	Vogt & Kord,[16]
Multiple drug analysis	RP-HPLC	Screening + optimization DoE	Reduced development time	Limited regulatory discussion	Phadke et al. [7]

Collectively, the literature summarized in Table 1 demonstrate that analysis of reported AQbD-based chromatographic studies indicates that reversed-phase HPLC remains the most frequently employed platform for method optimization. Statistical experimental designs such as factorial and central composite designs are commonly used to evaluate critical method parameters and establish design spaces. Most studies focus on assay determination and stability-indicating methods, while fewer investigations address combination drug analysis or lifecycle performance monitoring. Additionally, the application of AQbD in advanced platforms such as LC–MS remains comparatively limited, highlighting opportunities for further research.

6. Advantages of AQbD Approach

The Analytical Quality by Design (AQbD) approach enhances the reliability and efficiency of analytical method development through predefined objectives, systematic experimentation, and lifecycle monitoring. AQbD promote predictive decision-making and provides regulatory advantages for chromatographic methods with multiple influencing variables.

6.1 Enhanced Method Robustness

One of the most significant advantages of AQbD is the improvement in method robustness. Traditional analytical development often produces methods that perform well under specific conditions but may fail when minor variations occur during routine use. AQbD addresses this limitation by identifying critical parameters and evaluating their influence through statistical experimentation. The establishment of a defined operating region ensures that the method can tolerate small fluctuations in conditions such as mobile phase composition, temperature, or flow rate without compromising analytical performance. As a result, AQbD-based methods demonstrate greater consistency during routine quality control, method transfer, and long-term use.

6.2 Reduced Variability

AQbD promotes a systematic understanding of sources of variability by linking method parameters with performance outcomes. Risk assessment tools and experimental designs allow the identification of variables that significantly influence analytical results. By controlling these variables within defined ranges, AQbD minimizes unexpected variability and reduces out-of-specification results. This predictive control is particularly valuable in chromatographic techniques where complex parameter interactions can otherwise lead to inconsistent separation or quantification.

6.3 Improved Regulatory Acceptance

Regulatory agencies increasingly encourage science-based analytical development approaches that demonstrate method understanding rather than relying solely on validation data. AQbD generates comprehensive knowledge regarding parameter effects, risk mitigation strategies, and method performance across operating ranges. This structured evidence supports regulatory submissions by providing scientific justification for method conditions and allowable adjustments. Guidance from organizations such as the International Council for Harmonisation highlights lifecycle thinking and risk management, principles that are inherently aligned with AQbD. Consequently, AQbD-based methods often experience

smoother regulatory review and greater flexibility during post-approval changes.

6.4 Efficient Resource Utilization

Although AQbD requires systematic planning at the initial stage, it ultimately improves resource efficiency. Statistical experimental designs reduce the number of trial-and-error experiments by evaluating multiple factors simultaneously. This approach decreases solvent consumption, analyst time, and instrument usage while accelerating method optimization. Additionally, robust methods reduce the need for repeated troubleshooting and revalidation, leading to long-term cost savings.

6.5 Better Scientific Understanding

AQbD emphasizes knowledge generation throughout method development. Instead of focusing only on achieving acceptable validation results, the approach investigates how and why analytical parameters affect performance. This deeper understanding supports rational decision-making, facilitates method transfer between laboratories, and enhances training of analytical scientists. The documentation of parameter interactions and risk relationships also provides a valuable knowledge base for future method development within similar analytical contexts.

6.6 Flexible Method Adjustments within MODR

A defining advantage of AQbD is the ability to make controlled adjustments within the Method Operable Design Region (MODR). Because acceptable performance is demonstrated across a multidimensional parameter space, minor modifications — such as small changes in solvent ratio or column temperature — can be implemented without requiring complete method redevelopment. This flexibility improves operational efficiency and supports lifecycle management, enabling analytical methods to adapt to instrument differences, column variability, or manufacturing changes while maintaining performance consistency. Overall, the AQbD approach strengthens analytical reliability by integrating scientific understanding, statistical optimization, and lifecycle thinking. The resulting methods are more resilient, adaptable, and aligned with modern pharmaceutical quality expectations, making AQbD a critical strategy for contemporary chromatographic method development.

7. Challenges and Limitations

Although Analytical Quality by Design (AQbD) offers substantial improvements in analytical method development, its practical implementation is associated with several challenges that

may limit widespread adoption. These challenges primarily arise from the need for multidisciplinary expertise, infrastructure requirements, and variability in regulatory interpretation. Understanding these limitations is essential for developing strategies that support effective integration of AQbD into routine analytical workflows.

7.1 Requirement of Statistical Expertise

AQbD relies heavily on statistical methodologies such as experimental design, response surface modeling, and multivariate data analysis. While these tools provide powerful insights into parameter interactions, they require a level of statistical understanding that may not be common among all analytical scientists. Interpreting model outputs, selecting appropriate experimental designs, and validating statistical assumptions can be complex. Inadequate statistical knowledge may lead to incorrect conclusions, inefficient experimentation, or underutilization of AQbD capabilities.

Consequently, structured training in statistical principles has become an important requirement for successful AQbD implementation.

7.2 Dependence on Specialized Software

The practical execution of AQbD frequently involves specialized software platforms used for experimental design, modeling, and visualization of design spaces. These tools facilitate efficient data analysis but introduce dependency on technological infrastructure and software licensing. Smaller laboratories or academic settings may face financial constraints that limit access to advanced statistical software. Additionally, effective use of these platforms requires training, which further increases implementation complexity. As a result, technological dependence can act as a barrier to routine adoption of AQbD.

7.3 Increased Initial Development Effort

Compared with traditional trial-and-error approaches, AQbD demands greater planning and documentation during the early stages of method development. Defining analytical objectives, conducting risk assessments, designing experiments, and establishing operating regions require additional time and effort. This increased upfront investment may be perceived as resource- intensive, particularly when rapid method development is required. However, while initial workload is higher, AQbD often reduces long-term effort by minimizing method failures, revalidation requirements, and troubleshooting activities.

7.4 Limited Awareness in Smaller Laboratories

Adoption of AQbD is uneven across the pharmaceutical sector. Large industrial organizations have increasingly integrated AQbD principles into analytical development, whereas smaller laboratories and academic institutions may have limited exposure to structured quality frameworks. Constraints related to training opportunities, infrastructure, and access to guidance materials contribute to this gap. Limited awareness can result in continued reliance on empirical development strategies, thereby restricting the broader implementation of predictive analytical approaches.

7.5 Lack of Uniform Regulatory Expectations

Although regulatory bodies encourage science-based analytical development, expectations regarding the extent of AQbD implementation are not always uniformly defined. Differences in interpretation across regions and organizations may create uncertainty regarding documentation requirements, design space justification, and lifecycle management practices. While guidelines from bodies such as the International Council for Harmonisation promote risk-based and lifecycle approaches, practical application can vary depending on regulatory context. This variability may discourage laboratories from fully adopting AQbD due to concerns about compliance clarity.

7.6 Strategies to Address Challenges

Addressing the limitations associated with AQbD requires coordinated efforts focused on education, standardization, and technological advancement. Training programs that strengthen statistical literacy among analytical scientists can improve confidence in experimental design and data interpretation. The development of user-friendly analytical software and open-source tools may reduce technological barriers. Furthermore, harmonized guidance and clearer regulatory expectations can support consistent implementation across organizations.

Overall, while AQbD introduces additional complexity during the initial stages of analytical development, its long-term benefits justify the investment. Overcoming existing challenges through capacity building and infrastructure development will be essential for expanding the adoption of AQbD and realizing its full potential in chromatographic method development.

8. Regulatory Perspective

Regulatory authorities increasingly encourage analytical methods developed through

scientific understanding and lifecycle thinking rather than reliance solely on end-stage validation. The AQbD framework aligns with this expectation by providing structured documentation that demonstrates how method performance is designed, evaluated, and maintained. Typical AQbD submissions include definition of the Analytical Target Profile (ATP), systematic risk assessment, justification of experimental design strategies, establishment of the Method Operable Design Region (MODR), and a clearly defined control strategy. Such documentation supports transparency and strengthens confidence in analytical reliability.

Guidance from organizations such as the International Council for Harmonisation and regulatory perspectives associated with the U.S. Food and Drug Administration emphasize risk-based development and lifecycle management of analytical methods. A key regulatory advantage of AQbD is the possibility of implementing method adjustments within the established design space without extensive revalidation. This flexibility facilitates efficient post-approval method changes while ensuring that analytical performance remains consistent and scientifically justified.

Table 2: Comparison of traditional and AQbD approach.

Feature	Traditional approach	AQbD approach
Development strategy	Trail-and-error based	Systematic, science-driven
Objective definition	Often undefined at start	Predefined Analytical Target Profile(ATP)
Parameter evaluation	One factor at a time	Multivariate evaluation using DoE
Understanding of variability	Limited	Comprehensive understanding of parameter interactions
Robustness	Evaluated late (during validation)	Built into method during development
Risk management	Minimal or informal	Structured risk assessment applied
Design space	Not established	Defined Method operable Design Region
Documentation	Focus on validation results	Knowledge rich lifecycle documentation
Troubleshooting	Reactive	Predictive and knowledge-based
Regulatory flexibility	Limited	Allows adjustments within design space
Resource utilization	Higher long-term rework	Efficient through planned experimentation
Lifecycle management	Rarely considered	Continuous monitoring and improvement

9. Current limitations and future Perspectives

The future of Analytical Quality by Design (AQbD) will be shaped by technological innovation and sustainable analytical practices. Increasing integration of green analytical chemistry aims to reduce solvent consumption, improve reagent safety, and enhance energy efficiency without compromising performance. Concurrently, artificial intelligence and

machine learning are enabling predictive optimization of chromatographic conditions, accelerating development and improving decision accuracy. Advances in automated experimentation, multivariate modeling, real-time monitoring, and digital data management are strengthening lifecycle verification and design space reliability.

Despite these advancements, important research needs remain. AQbD application to combination drug products is still limited due to analytical complexity, while green AQbD strategies require broader implementation. Advanced platforms such as LC–MS remain underexplored within AQbD frameworks because of additional variability factors. Furthermore, lifecycle monitoring is often insufficient, as many studies emphasize development and validation stages. Integration of data- driven tools into routine AQbD workflows is also at an early stage. Addressing these areas will be essential to improve robustness, sustainability, and lifecycle integration of AQbD-based chromatographic methodologies.

10. CONCLUSION

Analytical Quality by Design has emerged as a transformative framework for chromatographic method development by shifting analytical practice from empirical optimization toward systematic, science-based design. Through structured evaluation of method variables, establishment of operating regions, and continuous performance monitoring, AQbD enhances robustness, reproducibility, and long-term reliability of analytical procedures.

The implementation of AQbD supports regulatory expectations for lifecycle management and strengthens confidence in pharmaceutical quality by providing documented method understanding and risk control. As analytical science continues to evolve, the integration of AQbD with advanced digital tools, automation, and sustainable analytical strategies is expected to further expand its significance in modern pharmaceutical analysis.

REFERENCES

1. Das P, Maity A. Analytical quality by design (AQbD): A new horizon for robust analytics in pharmaceutical process and automation. Int J Pharm. Drug Anal., 2017; 5(8): 324-337.
2. Gupta KR, Ganorkar AV. Analytical quality by design: A mini review. Biomed J Sci. Tech. Res., 2017; 1(6): 1-5.
3. Bairagi A, Kothrukar R, Chikhale H, Kosanam S, Borse L. AQbD: Novel strategy for

analytical methods. Future J Pharm. Sci., 2024; 10: 138.

4. Sri KB, Fatima S, Sumakanth M. Analytical quality by design used in the pharmaceutical industry: A review. Drug Discov., 2023; 17: e22dd1930.
5. Raman NVVSS, Mallu UR, Bapatu HR. Analytical quality by design approach to test method development and validation in drug substance manufacturing. J Chem., 2015; 2015: 435129.
6. Ameen SA, Pappula N. Analytical QbD approach to redefine the quality of pharmaceuticals: A review. J Pharm. Res., 2023; 22(4): 178-185.
7. Phadke R, et al. A review on quality by design approaches to analytical method development. Indo Am J Pharm. Res., 2019; 9(7): 1-10.
8. ICH. Pharmaceutical development Q8(R2). International Council for Harmonisation; 2009.
9. ICH. Quality risk management Q9. International Council for Harmonisation; 2005.
10. ICH. Pharmaceutical quality system Q10. International Council for Harmonisation; 2008.
11. Rozet E, Lebrun P, Hubert P. Design of experiments for analytical method development. Trends Anal. Chem., 2013; 42: 157-167.
12. Hibbert DB. Experimental design in chromatography: A tutorial review. J Chromatogr B. 2012; 910: 2-13.
13. Ferreira SLC, et al. Box-Behnken design: An alternative for optimization. Anal Chim Acta. 2007; 597: 179-186.
14. Snyder LR, Kirkland JJ, Dolan JW. Introduction to modern liquid chromatography. 3rd ed. Hoboken: Wiley; 2010.
15. Swartz ME, Krull IS. Analytical method development and validation. Boca Raton: CRC Press; 2012.
16. Vogt FG, Kord AS. Development of quality-by-design analytical methods. J Pharm Sci. 2011; 100: 797-812.
17. Dejaegher B, Vander Heyden Y. Experimental designs in analytical chemistry. J Pharm Biomed Anal. 2011; 56: 141-158.
18. Fekete S, Guillarme D. Current role of UHPLC in pharmaceutical analysis. J Pharm Biomed., Anal. 2014; 87: 105-121.
19. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of stability-indicating methods. J Pharm. Anal., 2014; 4: 159-165.
20. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009; 27: 26-34.

21. Peraman R, Bhadraya K, Padmanabha Reddy Y. Analytical quality by design: A review. J Pharm. Anal., 2015; 5: 1-10.
22. Kumar VP, et al. Application of AQbD in RP-HPLC method development. Int J Pharm Sci. Rev. Res., 2018; 52: 50-58.
23. Monks K, Molnar I, Rieger HJ, Bogati B, Szabo E. Quality by design: Multidimensional modelling in HPLC. J Chromatogr A. 2012; 1232: 218-230.
24. Molnár I. Computerized design of separation strategies. J Chromatogr A. 2016; 1469: 71-81.
25. Bhutani H, Kurmi M, Singh S. Regulatory requirements for analytical methods. J Pharm Biomed., Anal., 2015; 102: 403-415.
26. Orlandini S, Pinzauti S, Furlanetto S. AQbD in pharmaceutical analysis. Anal. Bioanal. Chem., 2013; 405: 443-450.
27. Reid GL, et al. Lifecycle management of analytical methods. Pharm. Technol., 2013; 37: 1-8.
28. Welch CJ, et al. Greening analytical chemistry. Green Chem., 2010; 12: 195-203.
29. Pena-Pereira F, Wojnowski W, Tobiszewski M. Green analytical chemistry trends. Trends Anal Chem., 2020; 126: 115857.
30. Brereton RG. Chemometrics for pattern recognition. Chichester: Wiley; 2009.
31. FDA. Analytical procedures and methods validation for drugs and biologics. Silver Spring: US FDA; 2015.
32. Fekete S, Beck A, Veuthey JL, Guillarme D. Theory and practice of UHPLC. Anal Chem. 2014; 86: 535-547.
33. Dolan JW. Method robustness in HPLC. LC-GC North Am., 2012; 30: 1126-1132.
34. Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste B, Massart DL. Guidance for robustness testing. J Pharm. Biomed. Anal., 2001; 24: 723-753.
35. Snee RD. Statistical thinking and DoE. Qual. Eng., 2010; 22: 1-15.
36. Rathore AS. Roadmap for QbD implementation. PDA J Pharm. Sci. Technol., 2014; 68: 334- 349.
37. Sangshetti JN, et al. QbD approach for analytical method development. Saudi Pharm. J. 2017; 25: 111-118.
38. Hubert C, et al. Harmonization of AQbD terminology. Talanta. 2017; 168: 1-6.
39. Rozet E, et al. Analytical method lifecycle concept. J Chromatogr A. 2015; 1400: 1-12.
40. Guillarme D, et al. Analytical strategies in pharmaceutical sciences. Trends Anal Chem., 2018; 102: 1-15.

41. Orlandini S, Furlanetto S. Analytical quality by design in pharmaceutical analysis: Recent advances and future perspectives. Anal Bioanal. Chem., 2020; 412: 1-15.
42. Pena-Pereira F, Tobiszewski M. The evolution of green analytical chemistry. Trends Anal Chem., 2021; 138: 116223.
43. Fekete S, Veuthey JL, Guillarme D. New trends in UHPLC method development for pharmaceuticals. J Pharm. Biomed. Anal., 2021; 193: 113722.
44. Molnár I, Rieger HJ. Quality by design in chromatographic method development using modelling tools. J Chromatogr A. 2020; 1618: 460882.
45. Kumar R, Singh B. AQbD-based RP-HPLC method development: Recent applications. Int J Pharm Investig. 2021; 11: 1-10.
46. Reid GL, Morgado J, Barnett K. Lifecycle management of analytical procedures: Current regulatory expectations. Pharm Technol., 2021; 45: 28-36.
47. Guillarme D, Fekete S. Digitalization in pharmaceutical analysis. Trends Anal Chem. 2022; 147: 116536.
48. Rozet E, Hubert P. Analytical method lifecycle and AQbD implementation in industry. J Pharm. Biomed. Anal., 2022; 210: 114563.
49. Rathore AS, Kapoor G. Quality by design implementation in pharmaceutical development: Recent progress. PDA J Pharm. Sci. Technol., 2022; 76: 1-12.
50. Sangshetti JN, Shinde DB. Application of design of experiments in pharmaceutical analysis: Recent updates. Saudi Pharm. J. 2022; 30: 1280-1290.
51. Furlanetto S, Orlandini S. Chemometrics-driven AQbD strategies. Anal Chim Acta. 2021; 1150: 238209.
52. Bhutani H, Singh S. Risk-based analytical method development in pharmaceuticals. J Pharm. Biomed. Anal., 2021; 197: 113936.
53. Monks K, Molnár I. Multidimensional modelling in chromatographic optimization: Recent developments. J Chromatogr A. 2021; 1637: 461833.
54. Guillarme D, Veuthey JL. Advances in LC-MS method development for impurity profiling. J Pharm. Biomed. Anal., 2023; 222: 115096.
55. Pena-Pereira F. Green analytical chemistry metrics applied to pharmaceutical methods. Trends Anal. Chem., 2023; 158: 116879.
56. Orlandini S, Furlanetto S. Analytical design space concept in pharmaceutical methods. Anal Bioanal. Chem., 2023; 415: 1-13.
57. Rathore AS. Analytical quality by design: Implementation challenges and solutions. PDA J Pharm. Sci. Technol., 2023; 77: 200-212.

58. Rozet E, Hubert C. Statistical modelling in analytical method lifecycle. J Chromatogr A. 2024; 1712: 464384.
59. Guillarme D, Fekete S. Artificial intelligence in chromatographic method development. Trends. Anal. Chem., 2024; 170: 117427.
60. Molnár I. Computer-assisted AQbD workflow in pharmaceutical chromatography. J Chromatogr A. 2024; 1705: 464090.
61. Singh B, Kumar R. AQbD approach for combination drug analysis: Recent case studies. Int J Pharm Sci Rev Res., 2024; 78: 45-55.
62. Furlanetto S, Orlandini S. Integration of modelling and automation in analytical method development. Anal. Chim. Acta., 2025; 1230: 340-352.
63. Rathore AS, Kapoor G. Digital transformation of pharmaceutical quality by design. PDA J Pharm. Sci. Technol., 2025; 79: 1-14.
64. Guillarme D, Veuthey JL. Sustainable chromatographic strategies in pharmaceutical analysis. Trends Anal Chem., 2025; 176: 117921.
65. Rozet E, Hubert P. Future of analytical lifecycle management in pharmaceuticals. J Pharm Biomed. Anal., 2026; 235: 115622.